Reuters | Depomed Inc. said U.S. health regulators accepted the company’s
marketing application for its experimental pain drug, triggering a $10
million milestone payment from its licensee and sending its shares up 12
percent.
Inside these posts: Depomed
Visit our Filed page for categories. To browse by specific topic, see our Inside page. For a list of companies covered on this site, visit our Companies page.
